Cadrenal Therapeutics, Inc CVKD IPO will take place January, 20 on the NASDAQ exchange under the ticker CVKD.
The company is offering shares at an expected price of $5.00 per share with an insider lock-up period of 180 days ending on July 19, 2023.
See also: Benzinga IPO Calendar
About Cadrenal Therapeutics, Inc
Cadrenal Therapeutics, Inc is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease and atrial fibrillation (irregular heartbeat) or AFib
See also: Benzinga's Most Shorted Stocks
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
